Rani Therapeutics Holdings, Inc. (RANI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 3 | 0 | 0 | 1 | 2 | 5 | 6 |
| Operating profit | $m | -38 | -33 | ||||||
| Net profit | $m | -17 | -8 | -31 | -34 | -30 | -30 | -30 | -11 |
| EPS reported | $ | -0.45 | -0.27 | ||||||
| Operating cashflow per share | $ | -0.28 | -0.11 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.28 | -0.11 | ||||||
| Free cash flow | $m | -19 | -20 | ||||||
| Net debt | $m | -47 | -50 | ||||||
| Book value equity | $m | 33 | 39 | ||||||
| Book value per share | $ | 0.50 | 0.21 | ||||||
| Number of shares | m | 66.14 | 187.17 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.70 | 2.28 | ||||||
| P/S LTM | x | 54.68 | 18.31 | ||||||
| P/FCF LTM | x | -4.75 | -4.39 | ||||||
| EV/EBITDA LTM | x | -2.02 | -2.34 | ||||||
| EV/Sales LTM | x | 45.92 | 10.39 | ||||||
| Earnings Yield LTM | % | -33.23% | -20.23% | ||||||
| FCF Yield | % | -21.06% | -22.78% | ||||||
| Quality | |||||||||
| ROE | % | -89.89% | -129.93% | ||||||
| ROIC | % | -80.59% | -63.96% | ||||||
| Operating margin | % | -23.46% | -6.76% | ||||||
| Gross margin | % | +44.89% | +96.70% | ||||||
| FCF/Sales | % | -1151.4% | -417.04% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +58.85% | +374.42% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -4.35 | -5.73 | ||||||
| Net Debt/EBITDA | x | 0.38 | 0.04 | ||||||
| EBIT/Net interest | x | -13.25 | -28.22 | ||||||
| Net debt/market cap | % | +3.06% | +6.82% | ||||||
| Net debt/Equity | x | -1.42 | -1.27 | ||||||
| Gross debt/equity | x | 0.13 | 0.09 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Rani Therapeutics Holdings, Inc. (RANI)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free